Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QARS1 | P47897 | 1/20 | 0.34 |
| ▸ | GLB1 | P16278 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.31 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13789828 | 1.00 | QARS1 (0.34) | QARS1GLB1ALOX5LMNAALKBH5 | |
| SCHEMBL13789766 | 1.00 | QARS1 (0.34) | QARS1GLB1ALOX5LMNAALKBH5 | |
| SCHEMBL4416941 | 1.00 | QARS1 (0.34) | QARS1GLB1ALOX5LMNAALKBH5 | |
| SCHEMBL10369813 | 0.89 | ALOX5 (0.40) | QARS1GLB1ALOX5LMNA | |
| SCHEMBL24441279 | 0.89 | ALOX5 (0.40) | QARS1GLB1ALOX5LMNA | |
| SCHEMBL8512062 | 0.79 | ITGB3 (0.42) | LMNA | |
| SCHEMBL13789896 | 0.79 | ITGB3 (0.42) | LMNA | |
| SCHEMBL31202 | 0.79 | ITGB3 (0.42) | LMNA | |
| SCHEMBL8513040 | 0.79 | ITGB3 (0.42) | LMNA | |
| SCHEMBL28246779 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532109-B1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK SERONO SA (CH) | 2009-09-09 | — | — | EP | disclosed |
| CN-1330633-C | Pyrrolidine derivatives as oxytocin antagonists | APPLIED RESEARCH SYSTEMS (AN) | 2007-08-08 | — | — | CN | disclosed |
| US-7115754-B2 | Pyrrolidine derivatives as oxytocin antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-10-03 | — | — | US | disclosed |
| US-20060004020-A1 | Pyrrolidine derivatives as oxytocin antagonists | MERCK SERONO SA (CH) | 2006-01-05 | — | — | US | disclosed |
| CN-1678576-A | Pyrrolidine derivatives as oxytocin antagonists | APPLIED RESEARCH SYSTEMS (AN) | 2005-10-05 | — | — | CN | disclosed |
| EP-1532109-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Applied Research Systems ARS Holding N.V. (AN) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004005249-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-01-15 | — | — | WO | disclosed |
| EP-0182213-B1 | CARBAPENEM COMPOUNDS AND PRODUCTION THEREOF | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004020-A1 | Pyrrolidine derivatives as oxytocin antagonists | OXTR, PRLHR, AVPR1A | QARS1 2828/4885GLB1 3974/4885ALOX5 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.